Suppr超能文献

病灶内注射硫代硫酸钠治疗失能性肿瘤性钙化:两例报告。

Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.

机构信息

Service de rhumatologie, hôpital Lariboisière, centre Viggo Petersen, Paris, France.

AP-HP, Georges Pompidou European Hospital, Physiology Department, Paris Descartes University, and INSERM, Unit 1151, Paris, France.

出版信息

Semin Arthritis Rheum. 2017 Dec;47(3):451-455. doi: 10.1016/j.semarthrit.2017.05.013. Epub 2017 Jun 17.

Abstract

INTRODUCTION

Tumoral calcinosis (TC) is a difficult-to-treat complication that can occur during several diseases such as dermatomyositis or genetic hyperphosphatemia. It is a painful and disabling condition that can lead to local complications including joint mobility reduction, cutaneous ulceration and superinfection. For the largest lesions, the treatment relies essentially on surgery. Intravenous sodium thiosulfate (STS) is efficient to treat calciphylaxis in patients undergoing hemodialysis. Local injections of STS seem efficient in superficial calcifications.

OBJECTIVE

To report the efficacy and safety of intra-lesional injections of STS in tumoral calcinosis.

RESULTS

We report two cases of successful intra-lesional injections of STS. A 44-year-old woman, with a history of dermatomyositis, presenting large subcutaneous calcifications in the right elbow, and a 42-year-old man, with a history of familial tumoral calcinosis, presenting large intramuscular calcifications in the right buttock, received weekly intra-lesional of 1-3g STS injections for 12 and 21 months, respectively. In both cases, the treatment relieved pain and greatly reduced the tumoral calcinosis with a very significant functional improvement without specific adverse effects. In case 1, TC size decreased from 28.756.0mm at baseline to 21.530.6mm at M12 treatment (59% reduction). In case 2, TC reduced from 167.5204.3mm at baseline to 86.285.2mm at M21 treatment (79% reduction).

CONCLUSION

Local injection of STS could be a promising therapeutic strategy for large and deep TC lesions and could therefore be an alternative to surgery.

摘要

简介

肿瘤性钙化(TC)是一种难以治疗的并发症,可发生在多种疾病中,如皮肌炎或遗传性高磷血症。它是一种痛苦和致残的疾病,可导致局部并发症,包括关节活动度降低、皮肤溃疡和继发感染。对于最大的病变,治疗主要依赖于手术。静脉注射硫代硫酸钠(STS)对接受血液透析的钙化磷灰石患者有效。STS 的局部注射似乎对浅表钙化有效。

目的

报告 STS 瘤内注射治疗肿瘤性钙化的疗效和安全性。

结果

我们报告了两例 STS 瘤内注射成功的病例。一名 44 岁女性,有皮肌炎病史,右肘有大的皮下钙化;一名 42 岁男性,有家族性肿瘤性钙化病史,右臀部有大的肌肉内钙化,分别接受了每周 1-3g STS 瘤内注射 12 个月和 21 个月。在这两种情况下,治疗均缓解了疼痛,并大大减少了肿瘤性钙化,功能显著改善,无特殊不良反应。在病例 1 中,TC 大小从基线时的 28.756.0mm 减少到 M12 治疗时的 21.530.6mm(减少 59%)。在病例 2 中,TC 从基线时的 167.5204.3mm 减少到 M21 治疗时的 86.285.2mm(减少 79%)。

结论

STS 局部注射可能是一种很有前途的治疗大而深的 TC 病变的策略,因此可以作为手术的替代方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验